Direct reprogramming of induced neural progenitors

A new promising strategy for AD treatment

Siqiang Lai, Min Zhang, Dongsheng Xu, Yiying Zhang, Lisha Qiu, Changhai Tian, Jialin C Zheng

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

Original languageEnglish (US)
Article number7
JournalTranslational Neurodegeneration
Volume4
Issue number1
DOIs
StatePublished - Apr 18 2015

Fingerprint

Alzheimer Disease
Stem Cells
Induced Pluripotent Stem Cells
Nerve Degeneration
Neurofibrillary Tangles
Neural Stem Cells
Embryonic Stem Cells
Mesenchymal Stromal Cells
Amyloid
Ethics
Synapses
Cognition
Dementia
Safety

Keywords

  • Alzheimer's disease
  • Induced neural progenitor cells
  • Stem cell-based therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Direct reprogramming of induced neural progenitors : A new promising strategy for AD treatment. / Lai, Siqiang; Zhang, Min; Xu, Dongsheng; Zhang, Yiying; Qiu, Lisha; Tian, Changhai; Zheng, Jialin C.

In: Translational Neurodegeneration, Vol. 4, No. 1, 7, 18.04.2015.

Research output: Contribution to journalReview article

@article{de8c216c94e240e6ab68739cc9ce3c01,
title = "Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment",
abstract = "Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.",
keywords = "Alzheimer's disease, Induced neural progenitor cells, Stem cell-based therapy",
author = "Siqiang Lai and Min Zhang and Dongsheng Xu and Yiying Zhang and Lisha Qiu and Changhai Tian and Zheng, {Jialin C}",
year = "2015",
month = "4",
day = "18",
doi = "10.1186/s40035-015-0028-y",
language = "English (US)",
volume = "4",
journal = "Translational Neurodegeneration",
issn = "2047-9158",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Direct reprogramming of induced neural progenitors

T2 - A new promising strategy for AD treatment

AU - Lai, Siqiang

AU - Zhang, Min

AU - Xu, Dongsheng

AU - Zhang, Yiying

AU - Qiu, Lisha

AU - Tian, Changhai

AU - Zheng, Jialin C

PY - 2015/4/18

Y1 - 2015/4/18

N2 - Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

AB - Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

KW - Alzheimer's disease

KW - Induced neural progenitor cells

KW - Stem cell-based therapy

UR - http://www.scopus.com/inward/record.url?scp=84928821804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928821804&partnerID=8YFLogxK

U2 - 10.1186/s40035-015-0028-y

DO - 10.1186/s40035-015-0028-y

M3 - Review article

VL - 4

JO - Translational Neurodegeneration

JF - Translational Neurodegeneration

SN - 2047-9158

IS - 1

M1 - 7

ER -